Journal List > Korean J Gastroenterol > v.75(1) > 1142218

Lee, Lee, Kim, Lee, Kim, Kim, and Jung: Analysis of Prognosis according to Type of Health Insurance in Five Major Gastrointestinal Cancer Patients in Public Hospitals: Single-institution Retrospective Study

Abstract

Background/Aims

Public hospitals were established to provide high quality medical services to low socioeconomic status patients. This study examined the effects of public hospitals on the treatment and prognosis of patients with five-major gastrointestinal (GI) cancers (stomach cancer, colon cancer, liver cancer, bile duct cancer, and pancreatic cancer).

Methods

Among the 1,268 patients treated at Seoul National University Boramae Medical Center from January 2010 to December 2017, 164 (13%) were in the medicare group. The data were analyzed to identify and compare the clinical manifestations, treatment modality, and clinical outcomes between the groups.

Results

No statistically significant differences in the clinical data (age, sex), treatment method, and five-year survival rate were observed between the health insurance group and medicare group in the five major GI cancer patients. On the other hand, some medicare group patients tended more comorbidities and fewer treatment options than health insurance patients.

Conclusions

Public hospitals have a positive effect on the treatment and prognosis in medicare group patients with the five-major GI cancers.

Figures and Tables

Fig. 1

Five-year survival rate of patients between the health insurance group (group H) and medicare group (group M). (A) Stomach cancer. (B) HCC. (C) Colon cancer. (D) Biliary cancer. (E) Pancreatic cancer. F/U, follow up; HCC, hepatocellular carcinoma.

kjg-75-17-g001
Table 1

Baseline Clinical Characteristics of the Enrolled Patients

kjg-75-17-i001

Values are presented as mean±standard deviation or n (%).

H, health insurance; M, medicare; Inf, infinity.

aChi-square test; bFisher's exact test.

Table 2

Comparison of the Cancer Stage between the Health Insurance Group and Medicare Groups

kjg-75-17-i002

Values are presented as n (%).

SEER, Surveillance, Epidemiology, and End Results; H, health insurance; M, medicare.

Table 3

Comparison of the Treatment Modality between the Health Insurance Group and Medicare Groups

kjg-75-17-i003

Values are presented as n (%).

H, health insurance; M, medicare; CTX, chemotherapy; IMX, immunotherapy; RTX, radiation therapy.

Notes

Financial support This work was supported by a clinical research grant-in-aid from the Seoul Metropolitan Government Seoul National University (SMG-SNU) Boramae Medical Center (03-2017-25).

Conflict of interest None.

References

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–E386.
crossref
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015; 385:117–171.
pmid
3. Jung KW, Won YJ, Kong HJ, Lee ES. Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat. 2018; 50:303–316.
crossref pmid pmc
4. Ngoma T. World Health Organization cancer priorities in developing countries. Ann Oncol. 2006; 17 Suppl 8:viii9–viii14.
crossref
5. Romero Y, Trapani D, Johnson S, et al. National cancer control plans: a global analysis. Lancet Oncol. 2018; 19:e546–e555.
crossref
6. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011; 20:2006–2014.
crossref pmid pmc
7. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001; 22:91–113.
crossref pmid
8. Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst. 2008; 100:1763–1770.
crossref pmid pmc
9. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull. 1976; 39:21–36.
10. Han KT, Park EC, Kim SJ, et al. Factors affecting the quality of life of Korean cancer survivors who return to the workplace. Asian Pac J Cancer Prev. 2014; 15:8783–8788.
crossref pmid
11. Khang YH, Kim HR. Socioeconomic inequality in mortality using 12-year follow-up data from nationally representative surveys in South Korea. Int J Equity Health. 2016; 15:51.
crossref pmid pmc
12. Kim K, Kim JS. Factors influencing health-related quality of life among Korean cancer survivors. Psychooncology. 2017; 26:81–87.
crossref pmid
13. Myong JP, Kim HR. Impacts of household income and economic recession on participation in colorectal cancer screening in Korea. Asian Pac J Cancer Prev. 2012; 13:1857–1862.
crossref pmid
14. Lee KS, Chang HS, Lee SM, Park EC. Economic burden of cancer in Korea during 2000-2010. Cancer Res Treat. 2015; 47:387–398.
crossref pmid
15. Lee SK, Sobal J. Socio-economic, dietary, activity, nutrition and body weight transitions in South Korea. Public Health Nutr. 2003; 6:665–674.
crossref pmid
16. Young JL Jr, Roffers SD, Gloeckler Ries LA, Fritz AG, Hurlbut AA. SEER summary staging manual - 2000. Codes and coding instructions. Bethesda (MD): National Cancer Institute;2001.
17. Miura F, Takada T, Amano H, Yoshida M, Furui S, Takeshita K. Diagnosis of pancreatic cancer. HPB (Oxford). 2006; 8:337–342.
crossref pmid pmc
TOOLS
ORCID iDs

Ji Won Kim
https://orcid.org/0000-0002-1214-5544

Similar articles